Her2 Stocks List Ranked for 2024 | NYSE, NASDAQ &

Symbol	Grade	Name	% Change
GTHX	A	G1 Therapeutics, Inc.	0.00
ZYME	C	Zymeworks Inc.	-5.09
ELVN	C	Enliven Therapeutics, Inc.	-0.08
PBYI	C	Puma Biotechnology Inc	2.29
MRKR	D	Marker Therapeutics, Inc.	-5.51
ZNTL	D	Zentalis Pharmaceuticals, Inc.	3.04
GLSI	F	Greenwich LifeSciences, Inc.	-0.39
OLMA	F	Olema Pharmaceuticals, Inc.	-2.17

Related Industries: Biotechnology

Symbol	Grade	Name	Weight
CNCR	F	Loncar Cancer Immunotherapy ETF	2.93
BBC	D	Virtus LifeSci Biotech Clinical Trials ETF	1.92
ARB	B	AltShares Merger Arbitrage ETF	1.72
EVNT	B	AltShares Event-Driven ETF	0.77
XPH	B	SPDR S&P Pharmaceuticals ETF	0.64

Compare ETFs

Compare CNCR to BBC Compare CNCR to EVNT Compare CNCR to XPH

Date	Stock	Title
Nov 21	PBYI	PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
Nov 21	ZYME	Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21	ZYME	FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 21	PBYI	Puma commences Phase II trial of alisertib for breast cancer treatment
Nov 20	PBYI	Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Nov 17	MRKR	Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Nov 14	MRKR	Marker Therapeutics GAAP EPS of -$0.26, revenue of $1.93M
Nov 14	MRKR	Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Her2: Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2 (rodent), or ERBB2 (human), is a protein that in humans is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene isolated from avian genome. It is also frequently called HER2 (from human epidermal growth factor receptor 2) or HER2/neu.HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients.